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To determine whether rapid emergence of Salmonella 
enterica serovar Infantis in Israel resulted from an increase 
in different biotypes or spread of 1 clone, we characterized 
87 serovar Infantis isolates on the genotypic and phenotypic 
levels. The emerging strain comprised 1 genetic clone with 
a distinct pulsed-field gel electrophoresis profile and a com-
mon antimicrobial drug resistance pattern.
N
ontyphoid Salmonella enterica (NTS) is a common 
cause of foodborne illnesses worldwide. In industrial-
ized countries, S. enterica serovars Enteritidis and Typh-
imurium are responsible for most NTS infections (1). In 
Israel, the distribution of NTS infections differs from the 
global epidemiology for NTS by having a larger represen-
tation of serogroups C1 and C2 (serovars Virchow, Hadar, 
and Infantis) in addition to serovars Enteritidis and Typh-
imurium (2,3).
Analysis of annual trends of NTS infections in Israel 
during  1995–2009  shows  a  steady  decrease  in  the  inci-
dence of these infections, from 86.9 cases/100,000 persons 
in 1995 to 31.4/100,000 in 2005. During this period, the 
predominant serovars were Enteritidis, Typhimurium, Vir-
chow, and Hadar, followed by Infantis. Since 2006, annual 
incidence of NTS has started to increase, rising to 44.0 
cases/100,000 persons in 2009. This trend coincided with 
a sharp increase in incidence of serovar. Infantis from 1.2 
cases/100,000 persons in 2001 to 14.7/100,000 in 2009, a 
12-fold rise (Figure 1, panel A). The proportion of sero-
var Infantis increased from <10% of NTS in 1995–2005 to 
34% in 2009 (Figure 1, panel B). Furthermore, this steep 
increase in serovar Infantis from clinical (human) sources 
correlated with an elevated frequency of serovar Infantis 
DISPATCHES
1754  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 11, November 2010
Author affiliations: Sheba Medical Center, Tel-Hashomer, Israel (O. 
Gal-Mor); Ministry of Health Laboratories, Jerusalem, Israel (L. Val-
insky, S. Guy, J. Jaffe, Y.I. Schorr, A. Raisfeld, V. Agmon, I. Nissan); 
and Assaf Harofeh Medical Center, Zerifin, Israel (M. Weinberger)
DOI: 10.3201/eid1611.100100
Figure  1.  Salmonellosis  epidemiology  in  Israel,  1995–2009.  A) 
Annual incidence of salmonellosis in Israel. Laboratory-confirmed 
cases of Salmonella infections per 100,000 population caused by 
all Salmonella serotypes (black) and by the 5 leading serotypes in 
Israel. B) The relative contribution (in percentages) of each serotype 
to the total annual number of Salmonella serotypes. Salmonella 
infection incidences were constructed according to the number of 
human Salmonella isolates submitted to the Government Central 
Laboratories during January 1, 1995–December 31, 2009 (after 
excluding repeated isolates from the same patient). Data on the 
Israeli population were derived from the publications of the Israeli 
Bureau of Statistics. C) Prevalence of S. enterica serovar Infantis 
and other leading serotypes in poultry. The proportion of different 
Salmonella  serotypes  as  percentage  from  the  total  Salmonella 
isolates in poultry was analyzed according to routine surveillance 
in poultry processing plants conducted by veterinary services in 
1998–2009.  Salmonella  isolates  have  been  received,  identified, 
and documented in the National Salmonella Reference Center of 
Israel.S. enterica Serovar Infantis, Israel
from poultry that became apparent after 2006. Serovar In-
fantis became the predominant serotype in poultry during 
2007–2009, while the prevalences of serovars Enteritidis, 
Typhimurium,  Virchow,  Bredeney,  Newport,  and  Para-
typhi B var. Java decreased (Figure 1, panel C).
The Study
Molecular analysis was used to study whether the rap-
id emergence of S. enterica ser. Infantis resulted from a 
general increase in different biotypes or a successful spread 
of 1 clone. Seventy-one randomly selected isolates of S. 
enterica ser. Infantis identified in Israel during 2007–2009 
(21 human sources, 28 poultry sources, and 22 food sourc-
es)  and  16  historical  strains  isolated  during  1970–2005 
(12 human sources, 2 poultry sources, and 2 food sources) 
were subjected to pulsed-field gel electrophoresis (PFGE). 
Macrorestriction with the XbaI enzyme discriminated the 
isolates into 23 distinct profiles (pulsotypes), designated 
I1–I23. Although the historical isolates showed high di-
versity in their PFGE patterns, most (58/71, 82%) recent 
(2007–2009) isolates were homogeneous and showed an 
indistinguishable PFGE profile (pulsotype I1), which was 
not found among the historical isolates (Figure 2; online 
Appendix  Table,  www.cdc.gov/EID/content/16/11/1754-
appT.htm). These results indicate that most of the emerging 
isolates belong to 1 genetic clone that probably started to 
spread in Israel sometime during 2005–2007. Furthermore, 
comparison of the I1 pulsotype with other PFGE profiles 
through PulseNet (www.cdc.gov/pulsenet/) and PulseNet 
Europe  (www.pulsenetinternational.org/networks/europe.
asp) indicated a pattern not reported elsewhere, suggesting 
the emerging clone is endemic to Israel.
To further characterize the isolates, we performed sus-
ceptibility tests to 16 antimicrobial compounds. Overall, 
resistance to 11 antimicrobial agents was detected (Table; 
online Appendix Table). Two clear differences were found 
between the strains isolated before and after 2007. First, 
although 6/16 (38%) of the historical strains were sensi-
tive to all tested antimicrobial agents and 5/16 (31%) were 
resistant to only 1 (nitrofurantoin), none of the 2007–2009 
isolates were sensitive to all of the tested antimicrobial 
agents. Most (68/71, 96%) of the recent isolates were resis-
tant to >3 antimicrobial agents, which suggests a process of 
resistance acquisition over time. Second, whereas isolates 
from 1970–2005 did not share any obvious resistance pat-
tern, most (66/71, 93%) of the 2007–2009 strains showed 
a combined resistance pattern to nalidixic acid, nitrofuran-
toin, and tetracycline with or without additional resistance 
to  trimethoprim/sulfamethoxazole  (Table).  The  conver-
gence of the recent serovar Infantis clones to a dominant 
resistance pattern is consistent with their common PFGE 
profile and shows that they share high similarity on pheno-
typic and genotypic levels.
Next, we characterized the molecular mechanisms re-
sponsible for the common antimicrobial drug–resistance 
phenotype. In bacteria, an efficient means of acquisition 
and dissemination of resistance genes is through mobile ge-
netic elements such as plasmids, transposons, or integrons 
(5). Plasmid analysis for 15 emerging (2007–2009) and 7 
historical (1970–2005) randomly selected isolates demon-
strated that all possessed 1 large plasmid of ≈100 kb. To 
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Figure  2.  Pulsed-field  gel  electrophoresis  (PFGE)  patterns  of 
Salmonella  enterica  serovar  Infantis  isolates  from  clinical,  food, 
and poultry sources isolated in Israel, 1970–2009, showing a high 
degree of clonality. Isolate number, year of isolation, and source are 
indicated. Bracket indicates I1 pulsotype pattern. Macrodigestion 
performed  using  XbaI  restriction  enzyme  and  genetic  similarity 
(in  %)  was  based  on  dice  coefficients.  PFGE  was  conducted 
according  to  the  standardized  Salmonella  protocol  Centers  for 
Disease  Prevention  and  Control  PulseNet  as  described  (4)  by 
using S. enterica ser. Braenderup H9812 strain as a molecular size 
standard. Because of space limitations, only 34/58 pulsotype I1 
clones are shown. A complete list is provided in the online Appendix 
Table (www.cdc.gov/EID/content/16/11/1754-appT.htm) identify antimicrobial drug resistance genes that are possi-
bly encoded on this plasmid, mating experiments were con-
ducted with a plasmid-free, rifampin-resistant Escherichia 
coli J5–3 strain and recent S. enterica ser. Infantis isolates 
harboring  tetracycline,  nalidixic  acid,  and  nitrofurantoin 
resistance genes. Conjugation experiments showed the ob-
tained E. coli transconjugants received the large (≈100-kb) 
plasmid and acquired the tetracycline resistance phenotype 
but remained susceptible to nalidixic acid and nitrofuran-
toin. We concluded the tetracycline resistance gene(s) is 
encoded on the conjugative plasmid. Molecular analysis 
by PCR showed the tetA gene encoded within the Tn1721 
transposon in 6 of 6 randomly selected emerging isolates 
but in only 1 of 5 older historical strains.
We examined class 1 integrons using PCR primers de-
signed to amplify the variable region of class 1 integrons. 
All 6 recent isolates bore 1 integron with a variable region 
of ≈1 kb. Sequencing of the resulting amplicon showed the 
dfrA1 gene cassette conferring resistance to trimethoprim–
sulfamethoxazole followed by the orfC gene of unknown 
function. In contrast, 3/5 historical isolates did not possess 
any integron, and 2/5 contained a disparate integron with a 
variable region of ≈1.3 kb. Sequencing analysis indicated 
a different cassette encoded by the aminoglycoside adenyl-
transferase aadA1 gene conferring resistance to spectino-
mycin and streptomycin.
Resistance to quinolones is often associated with point 
mutations in the quinolone-resistance determining region 
of the gyrA gene (6). To examine this possibility, we de-
termined the gyrA sequence from 6 recent naladixic acid–
resistant and 4 naladixic acid–sensitive isolates. All resis-
tant clones showed the same nucleotide substitution from 
guanine to thymine at position 259 (G259T) in the gyrA 
gene, resulting in the exchange of asparagine in position 
87 to tyrosine (Asp87Tyr) in the quinolone resistance–de-
termining region domain. No mutations were found in the 
gyrA sequence of the naladixic acid–sensitive isolates, sug-
gesting that the Asp87Tyr point mutation is responsible for 
the observed naladixic acid–resistance phenotype.
Conclusions
It  is  likely  that  environmental  selective  pressure 
caused by use of antimicrobial drugs has led to the dis-
tribution of appropriate resistant genes. Nitrofurans and 
sulfonamides, for example, have been widely used to treat 
infections and promote growth of livestock (7). Because 
the emerging clone was dominant in all levels of the food 
chain, including broiler chickens, it is possible that the 
emerging clone was originally introduced from a poul-
try source. Recent studies from other countries identified 
healthy poultry as a potential reservoir of S. enterica ser. 
Infantis (8–10).
Molecular and phenotypic characterization of recent 
S. enterica ser. Infantis isolates from different sources and 
regions in Israel showed high homogeneity of emerging 
isolates  that  differ  genetically  and  phenotypically  from 
previously isolated strains. We showed that the emerging 
clone is multidrug resistant and is characterized by a large 
conjugative plasmid harboring the Tn1721 transposone and 
tetA gene, which provides reduced susceptibility to tetra-
cyclines. Additional characteristics include a class 1 inte-
gron containing the dfrA1 cassette, a gyrA mutation that 
mediates nalidixic acid resistance and furthers resistance 
to nitrofurantoin. Our results suggest the recent emergence 
of serovar Infantis is an outcome of a clonal expansion and 
establishment of a specific biotype that took place during a 
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Table. Antimicrobial drug resistance patterns of Salmonella enterica serovar Infantis isolates, sorted by isolation year, Israel* 
Antimicrobial drug resistance profile 
PFGE pattern 
1970–2005  2007  2008  2009  Total
I1 D I1 D I1 D I1 D
Ampicillin, cefuroxime, ceftriaxone, cephalothin, 
nitrofurantoin, trimethoprim/sulfamethoxazole 
1  1 
Ampicillin, cefepime, ceftriaxone, cephalothin, 
cefuroxime, tobramycin 
1  1 
Nitrofurantoin  5 5
Nitrofurantoin, tetracycline  1 1
Levofloxacin, nalidixic acid  1 1
Nalidixic acid, nitrofurantoin, tetracycline  1 1 37 3 8 3 53
Nalidixic acid, nitrofurantoin, tetracycline, cephalothin  1 1
Nalidixic acid, nitrofurantoin, tetracycline, 
trimethoprim/sulfamethoxazole
2 1 1 10 1 15
Nalidixic acid, tetracycline, 
trimethoprim/sulfamethoxazole
1 1
Nalidixic acid, tetracycline  1 1
Nalidixic acid, trimethoprim/sulfamethoxazole  1 1
Sensitive to all tested antimicrobial drugs  6 6
Total 16 2 3 47 7 9 3 87
*PFGE, pulsed-field gel electrophoresis; I1, emerging PFGE pattern; D, different from the emerging pattern. S. enterica Serovar Infantis, Israel
relatively short period. Virulence mechanisms contributing 
to this phenomenon are the subject of an ongoing study.
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